Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment

Objectives This study aimed to evaluate the efficacy and safety of long-term postpartum tenofovir disoproxil fumarate (TDF) therapy in hepatitis B virus (HBV)-infected mothers with high viral load. Methods In this retrospective cohort study, HBV-infected mothers with HBV DNA>2 × 105 IU/mL who initiated TDF prophylaxis treatment during pregnancy were divided into TDF continuation and discontinuation groups according to whether they stopped TDF treatment within 3 months after birth or not. Virological and biochemical markers were collected before TDF treatment, antepartum and postpartum. Results In 131 women followed for a median of 18 months postpartum, alanine aminotransferase (ALT) abnormality rate was significantly lower in TDF continuation group vs. discontinuation group (39.4% vs. 56.9%, P = 0.045), and continuous TDF therapy in postpartum was independently associated with lower risk of ALT flares [OR = 0.308, 95% confidence interval (CI), 0.128–0.742; P = 0.009]. Long-term postpartum TDF treatment can promote the decline of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, but the HBeAg seroconversion rate in two groups was not significant (15.5% vs. 11.7%, P = 0.541). There were no statistical differences in bone metabolism markers between two groups (P > 0.05). Compared with the TDF discontinuation group, TDF continuation group had a significantly lower estimated glomerular filtration rate level and higher creatinine level in postpartum but within normal ranges (P < 0.05). Conclusions For pregnant women who received prophylactic TDF treatment, long-term TDF therapy continued in postpartum can reduce the risk of ALT flares and promote the rapid decline of HBeAg and HBsAg levels.

[1]  H. Xing,et al.  Antiviral Therapy for Prevention of Perinatal Hepatitis B Virus Transmission Reduces the Incidence of Postpartum Hepatitis Flare , 2022, BioMed research international.

[2]  Steven R. Martin,et al.  Real‐world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate‐treated chronic hepatitis B pregnant patients in North America , 2020, Alimentary pharmacology & therapeutics.

[3]  C. Pan,et al.  The safety of antiviral therapy and drug withdrawal for the prevention of mother‐to‐child transmission of HBV during pregnancy , 2020, Journal of medical virology.

[4]  C. Coffin,et al.  Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics , 2020, Hepatology communications.

[5]  S. Ahn,et al.  An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate , 2020, Journal of viral hepatitis.

[6]  S. Belle,et al.  Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study , 2019, The American journal of gastroenterology.

[7]  D. Cai,et al.  [Impact of cessation of antiviral therapy at delivery on postpartum liver function in mothers with chronic hepatitis B virus infection]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[8]  A. Garg,et al.  Serum Creatinine Levels Before, During, and After Pregnancy , 2019, JAMA.

[9]  Yang Ding,et al.  Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China , 2018, International journal of medical sciences.

[10]  J. Lewis,et al.  Incidence, determinants and outcomes of pregnancy‐associated hepatitis B flares: A regional hospital‐based cohort study , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[11]  Z. Wang,et al.  Safety and efficacy of telbivudine in late pregnancy to prevent mother‐to‐child transmission of hepatitis B virus: A multicenter prospective cohort study , 2018, Journal of viral hepatitis.

[12]  Ming Liu,et al.  The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B , 2018, The American Journal of Gastroenterology.

[13]  Zicheng Jiang,et al.  Baseline Hepatitis B Virus Titer Predicts Initial Postpartum Hepatic Flare: A Multicenter Prospective Study , 2017, Journal of clinical gastroenterology.

[14]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[15]  F. Cao,et al.  Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus , 2016, Journal of gastroenterology and hepatology.

[16]  Yue Chen,et al.  Effect of Peg‐interferon α‐2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[17]  H. Khalili,et al.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention , 2014, European Journal of Clinical Pharmacology.

[18]  S. Locarnini,et al.  Anti‐viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post‐partum flare , 2014, Alimentary pharmacology & therapeutics.

[19]  T. Skopek,et al.  A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function , 2010, Nature Biotechnology.

[20]  Z. Duan,et al.  [The guidelines of prevention and treatment for chronic hepatitis B]. , 2005, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.